TCM
TECH icon

Tuttle Capital Management’s Bio-Techne TECH Stock Holding History

Tuttle Capital Management’s Portfolio TECH Stock Details TECH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-14,520
Closed -$1.63M – 247
2021
Q2 		$1.63M Buy
+14,520
New +$1.53M 0.72% 36

Other funds holding TECH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
DDC
DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return

Tuttle Capital Management's TECH Position: Q3 2021 in Review

Tuttle Capital Management sold out of Bio-Techne (TECH) in Q3 2021, closing a stake of 14,520 shares — an estimated $1.63M sold.

Tuttle Capital Management first reported a position in TECH in Q2 2021 and held it in 1 quarter. The position peaked at $1.63M in Q2 2021. 565 funds tracked by Wall St. Rank hold TECH as of Q3 2021.

  • Tuttle Capital Management reported no remaining Bio-Techne position as of Q3 2021 after selling out during the quarter.
  • Tuttle Capital Management sold 14,520 Bio-Techne shares in Q3 2021, an estimated $1.63M.
  • Tuttle Capital Management first reported a position in Bio-Techne in Q2 2021 and held it in 1 quarter.
  • Tuttle Capital Management's Bio-Techne position peaked at $1.63M in Q2 2021.
  • 565 funds tracked by Wall St. Rank held Bio-Techne as of Q3 2021.

Based on Tuttle Capital Management's 13F filing for Q3 2021, filed 20 Oct 2021.